ea0084ps3-15-134 | Thyroid Cancer Diagnosis & Treatment | ETA2022
Hadoux Julien
, I Hu Mimi
, S. Brose Marcia
, Garralda Elena
, Spitzweg Christine
, Reguart Noemi
, Do Cao Christine
, D. Forster Martin
, Alonso-Gordoa Teresa
, Barata Teresa
, Scalori Astrid
, Zalutskaya Alena
, Trask Peter
, Subbiah Vivek
Objectives: RET alterations are targetable oncogenic drivers in TC. Patients with TC, especially those with MTC treated with the multikinase inhibitors cabozantinib and/or vandetanib (C/V), often experience significant treatment-related side effects. Pralsetinib, a selective RET tyrosine kinase inhibitor, showed efficacy in patients with RET-altered TC from the phase 1/2 ARROW trial (NCT03037385). We present the impact of pralsetinib on PROs in patients with ...